COLL as reported
Collegium Pharmaceutical, Inc. reported $796M of revenue over the trailing twelve months, +20% on the year before. 11 reported series are charted on this page, each one as filed.
$796M
Revenue, trailing twelve months · to Q1 2026 · +20% against the twelve months before
- Net Income
- $75M
Net Income · +71% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $330M
Free Cash Flow · +68% year on year · trailing twelve months to Q1 2026
- Op Margin
- 23%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $796M | +20% | Q1 2026 |
| Net Income | $75M | +71% | Q1 2026 |
| EPS | $2.04 | +67% | Q1 2026 |
| Gross Margin | 61% | n/a | Q1 2026 |
| Op Margin | 23% | n/a | Q1 2026 |
| Net Margin | 9.3% | n/a | Q1 2026 |
| ROE | 20% | n/a | Q1 2026 |
| ROA | 3.6% | n/a | Q1 2026 |
| ROIC | 25% | n/a | Q4 2019 · 25 quarters behind |
| Free Cash Flow | $330M | +68% | Q1 2026 |
| P/E | 13.5 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Collegium Pharmaceutical, Inc. (COLL) - Revenue & ProfitRevenue & ProfitCollegium Pharmaceutical, Inc. (COLL)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #13 of 28 by Smart Score